ABSTRACT - 596297 The disclosure relates to a use of a biocompatible and/or biodegradable polymer and an effective amount of a dopamine modulating compound in the manufacture of a biodegradable implant for treating a subject for a dopamine associated state wherein said dopamine modulating compound is a dopamine agonist selected from the group consisting of apomorphine lisuride pergolide bromocriptine pramipexole rotigotine docarpamine terguride cabergoline levodopa spheramine romergoline carmoxi...

585621 Disclosed is the use of a dopamine agonist in the manufacture of a medicament for preventing or reducing weight gain associated with administration of an atypical antipsychotic drug wherein the medicament when administered is administered simultaneously or sequentially with the atypical antipsychotic drug wherein the dopamine agonist is selected from the group consisting of pramipexole bromocriptine cabergoline pergolide ropinirole and quinagolide and wherein the atypical antipsychotic dr...

PURPOSE: An increase method of fused protein into living cells or organs by adding pergolide to fused protein in which protein transport domains and therapeutic protein are covalently bonded is provided to drastically enhance infiltration efficiency of the fused protein. CONSTITUTION: An increase method of fused protein into living cells or organs is processed by adding pergolide to fused protein in which protein transport domains and therapeutic protein are covalently bonded. The pergolide is p...

A cover material adapted to cover the entirety of a patch is provided.The cover material has a support layer and superimposed on a surface thereof a pressure sensitive adhesive layer.The patch has a support film with a thickness of 12- to 30 mum and superimposed thereon a drug containing layer.The cover material may be attached to the surface of the support film and to the skin around the patch so that the pressure sensitive adhesive layer is brought into contact with edges of the drug containin...

PROBLEM TO BE SOLVED: To provide a method for producing a pergolide preparation exhibiting sufficient stability without using cold form wrapping which is expensive and cannot be visually checked the inside.SOLUTION: The method for producing pergolide tablet comprises a step for preparing main drug granule comprising pergolide or its pharmaceutically permissible salt and sugar alcohol a step for preparing excipient granule containing neither pergolide nor its pharmaceutically permissible salt but...

PROBLEM TO BE SOLVED: To provide a medical agent effective to toxicity originated from a quinone compound or a precursor of quinone compound produced by oxidation of an exotic medical agent or endogenous amines amino acids or proteins and specifically effective to cranial neuropathy and/or cytopathy.SOLUTION: The invention relates to the suppressant of toxicity due to the quinone compound or precursor of the quinone compound comprising a compound selected from a group comprising dopamine recepto...

FIELD medicine pharmaceutics. ^ SUBSTANCE claimed is application of dopamine agonist (for instance amantadine bromocriptine cabergoline quinagolide lisuride pergolide ropinirole and pramipexole) for production of medication for treatment and prevention of endometriosis. ^ EFFECT reduction of number of active endo-metrioid niduses in treated niduses signs of atrophic or degenerative tissues were observed ie reduction of number of endometrial glands under action of cabergoline. ^ 14 cl 6 dwg 2 tbl...

The invention relates to a transdermal therapeutic system (TTS) for the transcutaneous administration of pergolide over several days and to a method for its manufacture without using solvents.The TTS contains a matrix mass containing pergolide and taking the form of a layer which contains a (meth)acrylate copolymer containing ammonio groups or a mixture of a (meth)acrylate copolymer containing amino groups and a (meth)acrylate polymer containing carboxyl groups 10-50% by weight propylene glycol ...

A cover material adapted to cover the entirety of a patch is provided. The cover material has a support layer and, superimposed on a surface thereof, a pressure sensitive adhesive layer. The patch has a support film with a thickness of 12- to 30 mum and, superimposed thereon, a drug containing layer. The cover material may be attached to the surface of the support film and to the skin around the patch so that the pressure sensitive adhesive layer is brought into contact with edges of the drug co...